Phase I-II Study of Dose Dense of PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma.

Trial Profile

Phase I-II Study of Dose Dense of PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Pegfilgrastim; Prednisone; Rituximab; Sargramostim; Vincristine
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Feb 2012 Genzyme added as trial sponsor as reported by ClinicalTrials.gov. (NCT01527422).
    • 09 Feb 2012 Genzyme added as trial sponsor as reported by ClinicalTrials.gov. (NCT01527422).
    • 20 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top